Indeed, therapeutic concepts have been proposed, for example, for KRAS mutant pancreatic cancer, in which the combined inhibition of mTORC1/2 and MEK precludes adaptive resistance [51]. The gene discussed is MAP2K7; the disease is familial pancreatic carcinoma.